Please login to the form below

Not currently logged in


This page shows the latest Riabni news and features for those working in and with pharma, biotech and healthcare.

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

The combination of Riabni, a biosimilar for Rituxan, with methotrexate is specifically for adult RA patients who have had one or more unsuccessful prior treatments. ... Riabni is not currently indicated for use as a treatment for children diagnosed with

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...